LabCorp participated in a $3m Series B2 financing round for Kiyatec, which is developing ex vivo 3D cell culture technology to help model and predict cancer patientsâ response to drug therapies.
Original Article: LabCorp joins $3m investment round for 3D cell culture tech firm Kiyatec